Immatics Newsroom

Immatics Analyst Ratings

BenzingaNov 19 12:32 ET

BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsNov 19 09:31 ET

Jefferies Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 19 08:31 ET

Leerink Partners Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $18

Moomoo NewsNov 19 03:39 ET

BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $15

Moomoo NewsNov 19 03:36 ET

Immatics' Promising Immunotherapy Developments Bolster Jonathan Chang's Buy Rating

TipRanksNov 12 02:48 ET

Piper Sandler Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsNov 6 07:31 ET

Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)

TipRanksNov 6 07:16 ET

Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics

TipRanksOct 15 02:47 ET

Immatics Initiated at Overweight by Piper Sandler

Dow JonesOct 7 08:00 ET

Immatics Analyst Ratings

BenzingaOct 7 07:50 ET

Piper Sandler Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $19

Moomoo NewsOct 7 05:33 ET

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsSep 13 12:32 ET

Leerink Partners Remains a Buy on Immatics (IMTX)

TipRanksSep 11 02:10 ET

Immatics Analyst Ratings

BenzingaSep 5 11:21 ET

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsAug 16 06:31 ET

Buy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside Potential

TipRanksAug 16 06:05 ET

BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsAug 14 05:34 ET

Buy Rating Affirmed on Immatics' Promising Pipeline and Upcoming Data Catalysts

TipRanksAug 14 04:42 ET

Immatics Analyst Ratings

BenzingaMay 16 07:11 ET